KIR Genotyping for NK Cell Therapy: Why Donor Selection Starts With the Right Typing

For allogeneic NK cell therapy programs, donor selection is not a procurement decision. It is a manufacturing decision. The donors you collect from determine the functional activity profile of the NK cells you produce, and KIR genotype is one of the most predictive donor variables for that functional profile. Most leukopak suppliers do not perform KIR genotyping as a standard donor characterization step. OrganaBio does it on every donor.

This piece explains what KIR genotyping is, why it matters for NK cell therapy starting material selection, how KIR haplotype and KIR-ligand interactions predict NK cell functional capacity, and what a standard KIR-typed donor pool enables for NK programs that a standard untyped pool does not.

What KIR Receptors Are and Why They Matter

Killer immunoglobulin-like receptors (KIRs) are a family of cell surface receptors expressed primarily on natural killer cells and a subset of T cells. They regulate NK cell activation and inhibition by binding to HLA class I ligands on target cells. The balance between activating and inhibitory KIR signals is the primary mechanism through which NK cells decide whether to kill a target cell.

The KIR gene family is located on chromosome 19q13.4. It contains 15 genes and two pseudogenes. Not every individual expresses every KIR gene — the KIR gene cluster is highly polymorphic, and the specific genes present in any individual’s KIR locus determine which receptors their NK cells express and how their NK cells respond to HLA class I ligands on potential target cells.

This is why KIR genotyping matters for NK cell therapy. An NK cell line derived from a donor whose KIR gene complement includes potent activating receptors that recognize tumor HLA ligands will behave very differently from an NK cell line derived from a donor whose KIR complement is dominated by inhibitory receptors that suppress killing of the same target. The difference is in the donor’s genome, and it is deterministic, not stochastic.

KIR Haplotypes: Group A and Group B

KIR genes are organized into two major haplotype groups based on the activating-to-inhibitory receptor ratio they encode.

Group A haplotypes contain a fixed set of genes encoding predominantly inhibitory KIR receptors: KIR3DL3, KIR2DL3, KIR2DL1, KIR2DL4, KIR3DL1, KIR2DS4, and KIR3DL2. Group A haplotypes have a single activating receptor gene (KIR2DS4) along with inhibitory KIR2DL1 and KIR2DL3. NK cells from Group A donors tend to have higher inhibitory signaling capacity relative to activating capacity.

Group B haplotypes are more variable and can contain additional activating receptor genes, including KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1. Donors with centromeric and telomeric B haplotype content have NK cells with higher activating receptor expression. Published research has associated Group B haplotype content, particularly the B/x genotype (at least one Group B haplotype), with improved NK cell responses in allogeneic transplantation and with better outcomes in KIR-ligand mismatch scenarios.

For allogeneic off-the-shelf NK cell therapy programs, donors with higher activating KIR content — more B-content haplotypes, more activating receptor gene copies — typically produce NK cell lines with stronger cytotoxic activity against KIR-ligand-mismatched tumor targets. Selecting donors with specific KIR haplotype content is the mechanism through which programs can enrich their starting material pool for donors most likely to yield high-activity NK cell lines.

KIR-Ligand Interactions: What the Pairing Means for Target Killing

KIR function is not determined by KIR genotype alone. It is determined by the pairing between the donor’s KIR genes and the HLA class I ligands expressed on target cells. The key receptor-ligand pairs in the NK cell therapy context:

• KIR3DL1 and HLA-Bw4. KIR3DL1 is an inhibitory receptor expressed on a large fraction of NK cells in most donors. It binds to HLA-Bw4 alleles. In a KIR-ligand mismatch scenario, tumor cells lacking HLA-Bw4 (or expressing HLA-Bw6 instead) lose inhibitory signaling to KIR3DL1-expressing NK cells, releasing those NK cells from inhibition and enabling killing. Donors who express KIR3DL1 are informative in this system; donors whose tumors lack HLA-Bw4 can be targeted by these NK cells.
• KIR2DL1 and HLA-C group 2 (HLA-C2). KIR2DL1 is an inhibitory receptor that binds HLA-C alleles carrying the C2 epitope (Asn77, Lys80). Donor NK cells expressing KIR2DL1 are inhibited by HLA-C2+ targets. In C2-negative targets, this inhibitory signal is absent.
• KIR2DL2/2DL3 and HLA-C group 1 (HLA-C1). The inhibitory receptors KIR2DL2 and KIR2DL3 bind HLA-C1 alleles (Ser80). Donors expressing KIR2DL2 or KIR2DL3 are inhibited by HLA-C1+ targets.
• KIR2DS1 and HLA-C2. KIR2DS1 is an activating receptor that binds HLA-C2 alleles. This is the mirror of KIR2DL1. NK cells from donors expressing KIR2DS1 can be activated (not inhibited) by HLA-C2+ targets — a situation relevant to programs targeting tumor cells that express HLA-C2.

The practical consequence: for a specific tumor target, the optimal donor has the activating receptors that recognize the target’s HLA profile and lacks (or under-expresses) the inhibitory receptors that would suppress killing of that target. Identifying that donor from a pool of uncharacterized leukopak donors requires either KIR genotyping at time of selection or retrospective genotyping of collected material after the fact. The latter is less efficient and more expensive. The former requires a supplier who has already done the genotyping.

Why Standard Donor Characterization Panels Miss This

Standard leukopak donor characterization covers the information required for general research and manufacturing use: viability, cell count, CD4/CD8 ratio, major cell fraction composition, HLA class I typing, donor health screening. This panel serves the majority of cell therapy starting material use cases well.

For NK cell therapy programs, the standard panel is incomplete. HLA typing tells you the donor’s HLA ligand profile. It does not tell you which KIR receptors the donor’s NK cells express or what their activating-to-inhibitory ratio looks like. Without KIR genotyping, a program selecting NK cell therapy starting material from a leukopak catalog is selecting from an uncharacterized KIR universe, without the information needed to identify donors whose NK cells will perform best against their target indication.

This is not a hypothetical limitation. NK cell therapy programs have discovered after manufacturing that starting material from certain donors produced consistently stronger cytotoxic NK lines than material from other donors, and retrospective KIR genotyping traced much of that variability back to KIR haplotype content. The programs that prospectively type and select for KIR genotype compress the discovery phase, improve manufacturing success rates per lot, and produce more consistent NK cell products across lots produced from different donors.

OrganaBio’s Standard KIR Typing Across All Donors

OrganaBio performs KIR genotyping on every donor in the leukopak program. This is not an add-on characterization service. It is standard. When an NK cell therapy program requests leukopak material from OrganaBio’s donor pool, the KIR genotype data is part of the standard donor record, available at time of selection.

The practical implications for NK cell therapy programs:

• Prospective donor selection by KIR content. Programs can specify KIR haplotype requirements — B-content donors, specific activating receptor presence (KIR2DS1, KIR3DS1), specific inhibitory receptor combinations — and select donors who meet those criteria from the existing characterized pool. This replaces the process of collecting from untyped donors and retrospectively genotyping to find the right profile.
• Manufacturing lot consistency. When every donor is typed, programs can restrict their starting material to donors with similar KIR profiles, producing more consistent NK cell products across manufacturing lots. This is a CMC consistency argument, not just a research argument.
• Correlation between donor KIR profile and NK line performance. As a program collects data on the manufacturing performance and functional activity of NK lines derived from different donors, OrganaBio’s KIR database provides the donor-side variable that can be correlated with those outcomes. This builds toward a predictive model for donor selection that improves as the dataset grows.

What to Request When Specifying NK Cell Therapy Starting Material

For NK cell therapy programs working with OrganaBio, the KIR specification in a starting material request should include:

KIR haplotype group. Group B-content donors (B/A or B/B genotype) for programs prioritizing activating receptor enrichment. Group A/A donors may be specified for programs specifically studying inhibitory KIR function or where inhibitory receptor expression is the research variable.

Specific activating receptor presence. KIR2DS1 presence for programs targeting HLA-C2+ tumors. KIR3DS1 presence for programs with HLA-Bw4 mismatch targeting. KIR2DS2 presence for programs with HLA-C1-targeted killing designs.

Inhibitory receptor profile. Whether KIR2DL1 homozygous donors need to be excluded (for programs where strong HLA-C2 inhibitory signaling would suppress activity against the target). KIR3DL1 expression level for programs where Bw4 inhibitory signaling is a relevant variable.

HLA typing correlated with KIR. The donor’s own HLA-C and HLA-B alleles matter for autologous KIR education and licensing. Programs should specify whether they need KIR-licensed or unlicensed NK cells based on the HLA-KIR pairing.

The KIR Education and Licensing Question

KIR education refers to the process through which NK cells become licensed to kill. An NK cell that expresses an inhibitory KIR for which it has no self-HLA ligand is hyporesponsive. NK cells are licensed to kill when their inhibitory KIR recognizes and binds self-HLA, receiving education that allows them to respond vigorously to cells lacking that self-HLA.

For allogeneic off-the-shelf NK programs, donor NK cells need to be licensed by their own HLA. This means the donor’s KIR-HLA pairing is relevant, not just the KIR genotype in isolation. A donor expressing KIR3DL1 who also carries HLA-Bw4 will have licensed KIR3DL1+ NK cells. A donor expressing KIR3DL1 without HLA-Bw4 will have unlicensed KIR3DL1+ NK cells with reduced reactivity.

OrganaBio’s paired KIR genotype and HLA typing data enables programs to identify donors with the specific KIR-HLA combinations that produce licensed, functional NK cells for their target biology. This paired data is not available from untyped donor pools regardless of their size.

Comparing Supplier KIR Typing Practices

OrganaBio is currently the only starting material supplier that markets standard KIR genotyping across its entire leukopak donor program. Other suppliers in the market either do not perform KIR genotyping as standard practice, offer it as a custom or add-on service that must be requested and adds lead time, or do not address it in their donor characterization documentation.

For programs in the evaluation phase comparing suppliers, the KIR question surfaces this distinction cleanly. Ask any supplier: is KIR genotyping standard on every donor in your leukopak program, or is it available as custom characterization? If the answer is custom, the practical implication is that the data will not be available at time of initial selection, and generating it adds lead time and often cost to the donor qualification process.

Applications Beyond Off-the-Shelf NK

While allogeneic off-the-shelf NK programs represent the highest-demand KIR context, KIR typing is relevant to several other research and manufacturing applications:

• KIR-HLA mismatch immunotherapy research. Programs studying the role of KIR-ligand mismatch in tumor immune evasion or in transplant tolerance require donors with defined KIR genotypes to build controlled experimental comparisons.
• NK cell expansion research. Protocols optimizing NK cell expansion conditions often need to control for donor KIR profile to separate the effect of the protocol from the effect of donor genetics on expansion efficiency.
• Mechanism of action studies for NK-engaging therapies. Programs developing bispecific NK cell engagers or antibodies that recruit NK cells (ADCC) benefit from knowing the KIR profile of the NK cell donors used in preclinical functional assays.
• Peripheral blood NK cell subtype characterization. Research programs characterizing CD56bright vs. CD56dim NK cells and their KIR expression patterns need donors with known KIR genotypes to correlate phenotype with genetics.

Working With OrganaBio for KIR-Typed NK Cell Therapy Starting Material

OrganaBio’s NK cell therapy starting material program combines standard KIR genotyping across all donors with GMP-capable leukapheresis processing and CTDMO services through the Excellos integration. Programs that need KIR-selected starting material for allogeneic NK programs, KIR-typed research material for mechanism studies, or a CTDMO partner who can process KIR-typed material through GMP manufacturing can access all three through OrganaBio’s program.

To discuss KIR-specific donor availability for your NK cell therapy or NK research program, contact OrganaBio. Provide your target indication, your KIR specification requirements, and your manufacturing timeline, and we will identify donors in the current pool that match your program specifications.

Frequently Asked Questions